NONOF - Novo Nordisk scoops up Embark Biotech amid foray into obesity
2023-08-30 09:48:11 ET
More on Novo Nordisk
- Novo Nordisk: Market Leader In A Growing Market
- Novo Nordisk: High Valuation Reflects Promising Outlook In Obesity Care
- Novo Nordisk: Denmark's Coca-Cola
- The Case For Novo Nordisk: Growth, Dividends, And A New Treatment Frontier
- Novo Nordisk Is A Hold Despite Explosive Growth In Diabetes And Obesity Care
- Novo Nordisk chief 'confident' Catalent Wegovy issues will be fixed - report
- Novo Nordisk said to have added Thermo Fisher for Wegovy production
- Drugmakers still chasing potentially lucrative NASH market, despite setbacks
- Novo Nordisk raises outlook as obesity franchise outperforms in Q2
For further details see:
Novo Nordisk scoops up Embark Biotech amid foray into obesity